The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Flaño, E.
Right arrow Articles by Blackman, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Flaño, E.
Right arrow Articles by Blackman, M. A.
The Journal of Immunology, 2005, 175: 3225-3234.
Copyright © 2005 by The American Association of Immunologists

Infection of Dendritic Cells by a {gamma}2-Herpesvirus Induces Functional Modulation1

Emilio Flaño*, Basak Kayhan{dagger}, David L. Woodland{dagger} and Marcia A. Blackman2,{dagger}

* Center for Vaccines and Immunity, Columbus Children’s Research Institute, Columbus, OH 43205; and {dagger} Trudeau Institute, Saranac Lake, NY 12983


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
The murine {gamma}-herpesvirus-68 ({gamma}HV68) establishes viral latency in dendritic cells (DCs). In the present study, we examined the specific consequences of DC infection by {gamma}HV68, both in vivo and in vitro. Ex vivo analysis of infected mice showed that the virus colonizes respiratory DCs very early after infection and that all subsets of splenic DCs analyzed are viral targets. We have developed and characterized an in vitro model of {gamma}HV68 infection of DCs. Using this model, we demonstrated that viral infection neither induces full DC maturation nor interferes with exogenous activation, which is assessed by cell surface phenotypic changes. However, whereas {gamma}HV68 infection alone failed to elicit cytokine secretion, IL-10 secretion of exogenously activated DCs was enhanced. Furthermore, {gamma}HV68-infected DCs efficiently stimulated virus-specific T cell hybridomas but failed to induce alloreactive stimulation of normal T cells. These data indicate that viral infection doesn’t interfere with Ag processing and presentation but does interfere with the ability of DCs to activate T cells. The inhibition of T cell activation was partially reversed by blocking IL-10. Analysis of infected mice shows elevated levels of IL-10 expression in DCs and that lack of endogenous IL-10 is associated with decreased {gamma}HV68 long-term latency. Taken together, these observations indicate that {gamma}2-herpesvirus infection of DCs is a mechanism of viral immune evasion, partially mediated by IL-10.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Dendritic cells (DCs)3 play a central role in initiating and modulating immune responses to pathogens (1, 2, 3, 4, 5, 6). Thus, many viruses have developed strategies for disrupting DC function (7, 8). This interference is possible at several levels of the DC induction of immunity: 1) maturation, viability, and migration of DCs; 2) Ag presentation; and 3) T cell activation and priming. A key question is whether interference with the initiation of immunity as a consequence of infection of DCs by chronic viruses constitutes a viral immune evasion mechanism.

{gamma}-Herpesviruses are oncogenic viruses associated with numerous malignancies and have significant health implications, especially in immunocompromised individuals (e.g., posttransplant or AIDS patients). More than 90% of the Western population carries EBV and between 1 and 8% is infected with Kaposi’s sarcoma-associated herpesvirus (KSHV). However, both viruses are endemic in several African regions, where KSHV seroprevalence exceeds 60% (9). Kaposi’s sarcoma is the most common reported neoplasm in many African counties, partially due to the AIDS epidemic, and represents a largely unseen and unchallenged public health problem (9).

{gamma}-Herpesvirus infections are characterized by the establishment of lifelong latency in the immunocompetent host. After an acute and generally asymptomatic infection, the infectious virus is cleared, and the virus persists in a latent state. Whereas the major reservoir of latent EBV, a {gamma}1-herpesvirus, is the memory B cell, KSHV, a {gamma}2-herpesvirus, targets a variety of cell types, including DCs (10, 11, 12). It has been reported that DCs derived from patients with Kaposi’s sarcoma are functionally impaired (13), but nothing is known about the specific consequences of DC infection by {gamma}2-herpesviruses.

Characterization of a murine {gamma}2-herpesvirus, MHV-68 or {gamma}HV68, has provided an important in vivo experimental model in which both the virus and the host can be manipulated. There are substantial genetic and biological similarities between {gamma}HV68 and KSHV (14, 15, 16). As with KSHV, {gamma}HV68 establishes latency in a broad range of cell types, including B cells, macrophages, epithelial cells, and, importantly, DCs (17, 18, 19, 20). For example, we have shown that DCs are a major target of {gamma}HV68 latency in the spleen (17, 21) and that they are a long-term reservoir of persistent virus in a variety of anatomical sites (18). These data are consistent with the possibility that the virus exploits its ability to infect DCs as a mechanism for usurping DC function. In this report, we have characterized the in vivo viral reservoirs in splenic and lung DCs during acute infection and early latency and have developed an in vitro model of {gamma}HV68 infection of DCs to determine the impact of infection on DC function. Both the in vivo and in vitro data support the hypothesis that {gamma}2-herpesvirus infection of DCs results in immune evasion.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 Disclosures
 References
 
Animal procedures and virus infection

{gamma}HV68, clone WUMS, was propagated and titered on monolayers of NIH-3T3 fibroblasts. C57BL/6J mice were purchased from Taconic Farms and housed under specific pathogen-free conditions in BL3 containment. IL-10-deficient mice (B6.129P2-IL-10tm1Cgn/J) and control mice (C57BL/6) were purchased from The Jackson Laboratory. The Institutional Animal Care and Use Committees at Trudeau Institute and at Columbus Children’s Research Institute approved all studies described here. Mice were anesthetized with 2,2,2-tribromoethanol and intranasally inoculated with 4 x 102 PFU of virus in PBS.

Viral assays

Plaque assay. To determine the titer of infectious virus, lungs obtained at various times after infection were stored frozen and mechanically homogenized. The cells were broken by three quick successive cycles of freeze-thawing. The lytic virus concentration of the lung homogenates or of DC culture supernatants was determined in a standard plaque assay on NIH-3T3 fibroblasts. The next day, the monolayers were overlaid with carboxymethyl cellulose (Sigma-Aldrich). After 6 days of culture, plaques were quantitated after methanol fixation and Giemsa staining.

Infective center assay. Single-cell suspensions were obtained as described above. Duplicates of the cell sample were mechanically disrupted by a cycle of freeze-thaw. The intact (total infected cells) and disrupted (lytically infected cells) cell samples from each organ were plated in triplicate onto monolayers of NIH-3T3 cells in serial 10-fold dilutions in 12-well plates. The monolayers were overlaid, and the plaques were quantitated as described above. The number of latently infected cells was calculated as the difference between total and lytically infected cells.

Limiting dilution-nested PCR. The number of cells containing the {gamma}HV68 genome was determined by a combination of limiting dilution analysis (LDA) and nested PCR (18). The purified cells were serially diluted in uninfected NIH-3T3 fibroblasts in 96-well plates, lysed, and DNA amplified by nested PCR as previously described (18, 22) using primers specific for {gamma}HV68 ORF50. This procedure was able to consistently detect a single copy of the target sequence. Twelve replicates were assessed for each cell dilution, and linear regression analysis was performed to determine the reciprocal frequency (95% degree of confidence) of cells positive for {gamma}HV68 DNA. As controls of nested PCR, 104 NIH-3T3 cells/well with and without plasmid DNA containing the {gamma}HV68 ORF50 gene were included in each 96-well plate.

Cell purification and FACS analysis

Dendritic cells from spleen and lung were purified on a FACS Vantage SE/DIVA sorter (BD Biosciences) as described previously (18). Briefly, the cells were isolated after collagenase D (5 mg/ml; Roche) treatment for 45 min. Cells were next incubated with 5 mM PBS/EDTA for 10 min at room temperature to disrupt multicellular complexes. If needed, B and T cells were depleted using a mixture of anti-CD19 and anti-Thy-1.2 cell culture supernatants and magnetic beads (Dynal Biotech). The cells were Fc-blocked and stained with fluorochrome-conjugated Abs specific for CD11c, B220, CD8{alpha}, and CD4 or for CD11c, CD11b, CD5, and CD19.

FACS staining was performed on ~105 cells/sample with combinations of the following Abs: CD11c, CD80, CD86, F4/80, Kb, Db, CD54, I-Ab, and CD40. Samples were washed and resuspended in 1% paraformaldehyde diluted in PBS before analysis. Apoptosis analysis was performed using annexin V and propidium iodide. Flow cytometry data were acquired on a FACScan or FACSCalibur and analyzed using CellQuest (BD Pharmingen) and FlowJo (Tree Star).

Gardella gel electrophoresis

The resolution of episomal and linear {gamma}HV68 genomes in lung DCs purified as described above was done by Gardella gel analysis (23, 24, 25). The lysis and separating gels were prepared as described previously (24). Purified DCs were resuspended in loading buffer containing 20% Ficoll (Sigma-Aldrich) and 0.01% bromophenol blue and then loaded onto the gels. The sample was overlaid with lysis buffer containing 5% Ficoll, 1% SDS, and 1 mg/ml self-digested pronase (Calbiochem). The gels were run at 4°C at 40 V for 3 h and then at 160 V for 16 h. The gels were then sliced at 0.5-cm intervals, the agarose was digested, and the DNA was extracted using {gamma}-agarase (Promega) and ethanol precipitation, following the manufacturer’s instructions. The presence of {gamma}HV68 DNA in the samples was determined by PCR in a 25-µl reaction containing primers (6.25 µM each) specific for {gamma}HV68 (5'-GATGGAAACAGAAAACGAGCCC-3' and 5'-TCGCTTGTTTCTGGGGAGGTTT-3'; product 425 bp), 1 U of TaKaRa Ex Taq (Takara Biomedicals), 2.5 µl of 10x Ex Taq buffer (Takara Biomedicals), and 3 µl of dNTP mixture (Takara Biomedicals). Amplification was for 45 cycles (94°C, 60 s; 67°C, 60 s; 72°C, 30 s), followed by a 7-min extension at 72°C. The {gamma}HV68-containing B cell line S11, which has been shown to harbor both episomal and linear {gamma}HV68 DNA (19), and lytically infected NIH-3T3 fibroblasts were used as controls for the Gardella gel analysis.

Gene expression analysis

The {gamma}HV68 gene expression analysis on cultured DCs was performed as described previously (21). The size of the transcripts detected corresponded to the sizes previously determined for S11 cells, a {gamma}HV68-containing B cell line that has been shown to harbor both lytic and latent {gamma}HV68 DNA (19).

DC cultures

DCs were generated from bone marrow cultures in complete tumor medium supplemented with 20 ng/ml GM-CSF (PeproTech). On day 10, nonadherent cells were harvested, and DC purity was analyzed by FACS staining (CD11c+I-Ab+, >95%). Next, DCs were infected for 3 h with {gamma}HV68 multiplicity of infection (MOI) 1–10 at 37°C and cultured in complete tumor medium supplemented with 10 ng/ml GM-CSF.

Ag-processing assays

The T cell hybridoma Ag presentation assays were done as described previously (26). Control (noninfected and peptide-loaded) and infected DC cultures were used as APCs. Two-fold serial dilutions of the cells were prepared in 96-well flat-bottom plates, starting at 106 cells/well. Hybridoma cells (105/well) were then added to each well, and the plates were incubated for 20 h. The relative response of each hybridoma was measured with a standard IL-2 assay.

The T cell proliferation assays were done using a standard MLR. Briefly, 4 x 105 irradiated DCs were mixed with 2 x 105 allogeneic BALB/c T lymphocytes after enrichment by panning with rat anti-mouse IgG. All the reactions were conducted in triplicate in 96-well plates. After 72 h of incubation at 37°C, cultures were pulsed with 0.02 µCi/ml [3H]thymidine for 18 h, and incorporation into cellular DNA was subsequently determined. In some experiments, allogenic T cells were labeled with CFSE, and T cell proliferation was assessed on day 3 by CFSE dilution. Functional grade purified anti-mouse IL-10 Ab (clone JES5-2A5; eBioscience) was added at 10 µg/ml.

Detection of cytokines

For determination of cytokines, the supernatant of stimulated and control DC cultures was collected. Cytokine release (TNF-{alpha}, IL-1{alpha}, IL1{beta}, IL-6, IL-12, and IL-10) was assayed using the Beadlyte Multiplex Cytokine Detection System (Upstate Biotechnology) as described by the manufacturer.

For real-time PCR analysis of IL-10, total RNA from FACS-purified DCs from spleens and lungs of infected (5 and 14 days postinfection (dpi)) and uninfected mice was isolated using RNAqueous-4PCR (Ambion), according to the manufacturer’s instructions. cDNA was synthesized using Cloned AMV RT kit (Invitrogen Life Technologies), and gene expression was measured using the 5' nuclease TaqMan assay and ABI Prism 7700 sequence detection system (Applied Biosystems). Fold increase in signal relative to that of sorted-uninfected DCs was determined using the {Delta}{Delta}Ct calculations recommended by the ABI Prism 7700 manufacturer. The endogenous control used to normalize the sample specific message levels was GAPDH, for which levels of expression do not vary in response to infection and time points (data not shown). The primers and probe sequences for murine IL-10 were modified from Oberbergh et al. (27) and validated by Trudeau Institute Molecular Biology Facility, and the sequences are as follows: IL-10 forward primer, 5'-GAAGACCCTCAGGATGCGG-3', reverse primer, 5'-ACCTGCTCCACTGCCTTGCT-3', and IL-10 probe, 5'-TGAGGCGCTGTCATCGATTTCTCCC-3'.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 Disclosures
 References
 
Viral latency is maintained in every subset of splenic DCs

Previous studies of {gamma}2-herpesvirus latency have shown that a broad range of cell types become infected. KSHV has been shown to establish latency in vivo in B cells, monocytes/macrophages, DCs, and endothelial cells (10, 11, 12) and in vitro in cell lines of epithelial, endothelial, and mesenchymal origin (28). {gamma}HV68 latency has been reported in B cells, macrophages, DCs, and epithelial cells in the host (17, 18, 19, 20). We have shown previously that respiratory and splenic DCs are an important reservoir of {gamma}HV68 during the establishment of the latency phase and that splenic DCs harbor virus during long-term latency (18). However, it is not known which specific DC subsets contribute to viral persistence.

To identify which subsets of DCs harbor virus, splenic DCs were flow cytometrically sorted on the basis of surface expression of CD11c, CD8, CD4, and B220 (Fig. 1, left column) at the peak of latency establishment (14 days postinfection) and during long-term infection (3 mo postinfection). Four major DC subsets were analyzed, including 1) CD11c+CD8+CD4–, 2) CD11c+CD8–CD4+, 3) CD11c+CD8–CD4–, and 4) CD11c+B220+ cells. All subsets contained virally infected cells, and the frequency of infected cells consistently decreased from early to long-term latency (Fig. 1, right column). The data in Table Ipresent a detailed analysis of the frequencies of infection and the total number of infected cells in each different DC subpopulation. The results show similar frequencies of infection at 14 days and more marked differences at 3 mo after infection. However, because of the low number of infected DCs during long-term latency, these differences probably lack functional significance. Taken together, these data indicate that the major subsets of DCs are latently and stably infected.



View larger version (24K):
[in this window]
[in a new window]
  		FIGURE 1. {gamma}HV68 latency in different subsets of splenic DCs. The frequency of {gamma}HV68 genome-positive cells was determined by LDA-PCR assay in FACS-purified splenic DC subsets during the establishment of the latency phase of infection (14 days postinfection, •) and long-term latency (3 mo postinfection, {circ}). CD11c+CD8+CD4– (A), CD11c+CD8–CD4+ (B), CD11c+ CD8–CD4– (C), and CD11c+B220+(D).

 

View this table:
[in this window]
[in a new window]
  		Table I. {gamma}HV68 frequencies within splenic DC (CD11c+) subsets during the establishment and maintenance phases of latent infection

 
{gamma}HV68 infects respiratory DCs early after intranasal infection

Our recent observation that lung B cells are latently infected soon after intranasal inoculation (25) prompted us to ask how early lung DCs were infected during the acute respiratory infection. DCs were sorted on days 3, 7, and 11 after intranasal infection and subjected to LDA-PCR analysis to determine the frequency of cells harboring virus. As shown in Fig. 2A, the frequency of lung DCs harboring viral genome increased dramatically during the first week of infection, from a frequency of ~1 to 1100 on day 3 to ~1 to 14 on day 7. By day 11, the frequency had declined to 1 to 126. These data show that DCs are early targets of {gamma}HV68 during the acute phase of infection in the respiratory tract, which may have an impact on the initiation of the immune response in the host.



View larger version (29K):
[in this window]
[in a new window]
  		FIGURE 2. {gamma}HV68 establishes latency in lung DCs very early following respiratory infection. A, Representative graph of data obtained from LDA-PCR analysis of FACS-purified lung DCs (CD11c+CD11b+/– CD19–) harboring viral genome at the indicated times after infection. The proportion of wells positive by PCR is plotted against the number of cells per well. B, Lung DCs contain both latent (episomal) and lytic (linear) virus at day 3 after infection. Gardella gel analysis of DNA from FACS-sorted DCs from lungs 3 days after {gamma}HV68 infection. The gel picture shows PCR for viral DNA of sequential individual gel slices, starting from the top of the gel (left to right). The slower migrating episomal DNA indicates latent viral genome and the faster migrating linear DNA represents lytic viral genome, as confirmed by analysis of viral DNA isolated from S11 cells, a {gamma}HV68 latently infected B cell tumor line, which has been shown to contain both episomal and linear genomes (19 25 ).

 
To determine whether the initial infection of lung DCs is lytic or latent, we assessed the conformational state of {gamma}HV68 DNA. It has been shown that latent {gamma}-herpesvirus genomes are episomal (covalently closed circular), whereas replicating viral genomes are in linear conformation (23). Gardella gel analysis, which involves DNA electrophoresis after in situ lysis of cells, is able to distinguish linear DNA (lytic virus) from circular DNA (latent, episomal virus). To increase the sensitivity of the assay, the presence of viral DNA was determined by PCR. Thus, after electrophoresis, individual lines of the gel were sliced, and each was analyzed for the presence of viral DNA by PCR of the ORF50 gene. The data in Fig. 2B show the presence of DNA with migration properties of episomal DNA in lung DCs as early as day 3 after infection, which is consistent with early latent infection.

An in vitro model of {gamma}HV68 infection of DCs

To further investigate the consequences of {gamma}HV68 infection of DCs, we established an in vitro infection model. Bone marrow-derived DCs were grown with murine rGM-CSF and infected with {gamma}HV68 on day 10. Analysis of viral gene expression in infected cultures using RT-PCR revealed that both viral lytic cycle and latency candidate genes were expressed 24 h after infection (Fig. 3A). To determine whether the infection was productive, we measured the amount of free virus in the DC culture supernatant at different times after infection using a standard plaque assay. The data show a progressive increase of free virus in the culture medium with time after infection, which is consistent with a productive infection (Fig. 3B). Analysis of the viability of the {gamma}HV68-infected DCs and 3T3 fibroblasts (Fig. 3C) showed that, in contrast to infected fibroblasts, which are rapidly killed, the infected DC cultures maintain viability up to 3 days after infection. To eliminate the possibility that the infectious virus measured in Fig. 3B was being produced by a minor non-DC population contaminating the cultures and that the DCs themselves were not infected, we directly measured viral infection of purified DCs. Cultured DCs were FACS sorted into CD11c+ and CD11c– cells 24 h after infection, and the frequency of infection of the purified cells was determined by an infective center assay. As shown in Fig. 3D, 100% of the DCs (CD11c+, 95% of the culture) were infected by {gamma}HV68, whereas only 50% of the non-DCs (CD11c–, 5% of the culture) scored positive for virus.



View larger version (48K):
[in this window]
[in a new window]
  		FIGURE 3. Characterization of {gamma}HV68 infection of bone marrow-derived DC cultures. A, Analysis of viral gene expression 24 h after infection (MOI:2) by RT-PCR shows gene expression of {gamma}HV68-lytic and -latent cycle transcripts. B, Analysis of the production of progeny infectious virus in the supernatants of DC cultures at different times after infection. {gamma}HV68 titers were determined by plaque assay. C, Cell culture viability. Cell numbers were obtained by trypan blue exclusion at different times after infection. Virally infected 3T3 fibroblasts are included for comparison. D, Analysis of the efficiency of DC infection. Dendritic (CD11c+) and nondendritic (CD11c–) cells were FACS purified after 24 h of infection, and serial 10-fold dilutions of the cells were plated in 12-well plates in an infective center assay. The figure shows the number of PFU obtained in the wells receiving 10 or 1 purified cells. E, Analysis of the contribution of lytically and latently infected cells to the total number of infected cells in culture at 24 and 96 h after infection. The number of infected cells was determined using an infective center assay. F, Analysis of cell death in DC cultures 96 h after infection using annexin V/propidium iodide. The cells were gated previously as CD11c+ DCs. The numbers show the percentage of viable (lower left quadrant), apoptotic (lower right quadrant), and necrotic (upper quadrant) DCs.

 
Next, we analyzed the contribution of lytic and latent {gamma}HV68 infection in the cultures using the standard infective center analysis. As shown in Fig. 3E, between 20 and 35% of the cultured cells are latently infected. We also studied the mechanism of cell death in the infected DC cultures (Fig. 3F). The data indicate that DC death occurs by necrotic lysis, which correlates with the percentage of lytically infected cells in culture. Taken together, our results confirm that this in vitro infection model with {gamma}HV68 offers an excellent tool to study the interaction between a {gamma}2-herpesvirus and DCs.

{gamma}HV68 infection does not induce DC maturation

We next analyzed the phenotypic changes induced by {gamma}HV68 infection of DCs by FACS analysis 48 and 96 h after viral infection. {gamma}HV68 infection did not induce modulation of the surface expression of CD80, CD86, F4/80, Kb, Db, IAb, or CD40 (Fig. 4, green and red lines). The only phenotypic change observed was the up-regulation of CD54 (ICAM-1) by 96 h. CD54 is a ligand for the integrin {alpha}L chain, and it is involved in a variety of intercellular adhesions. Similar results were obtained with MOI from 1 to 10 at time points between 24 and 96 h after infection (data not shown). Thus, viral infection of DCs did not induce global cellular maturation or activation. To determine whether the failure of viral infection to induce cellular maturation or activation reflected a virus-induced impairment in the ability of the DCs to mature in response to other exogenous stimuli, we used two approaches. First, we analyzed phenotypic changes after LPS stimulation of infected and uninfected DCs. As shown in Fig. 4 (blue and gray lines), LPS induced the activation of the infected DCs to the same level as the uninfected cells. Second, to formally test the possibility that the lack of cell surface activation was due to shut off of the cellular machinery induced by ongoing viral replication and to determine whether this effect required viral gene expression, we repeated the phenotypic analysis using heat-inactivated virus or phosphonoacetic acid, an inhibitor of the viral polymerase (29). Similar to the results obtained with infectious virus, the addition of heat-inactivated {gamma}HV68 to DCs did not induce up-regulation of any of the markers analyzed (Fig. 5A, red and orange compared with green lines). Similarly, the addition of phosphonoacetic acid to the culture medium did not have any impact on the levels of expression of the cell surface molecules analyzed (Fig. 5, red and pink compared with green lines). This result indicated that the lack of DC activation was not mediated by the shut off of the cellular machinery due to viral replication and that viral structural proteins do not induce DC activation by themselves. Taken together, our results indicate that {gamma}HV68 infection does not fully activate DCs and that {gamma}HV68 infection does not impair the capacity of the infected cells to become activated by an exogenous signal.



View larger version (38K):
[in this window]
[in a new window]
  		FIGURE 4. {gamma}HV68 infection does not up-regulate expression of DC markers. Bone marrow-derived DCs were surface stained with CD11c and the indicated markers at 48 and 96 h after infection (MOI:2). The histogram populations were gated previously as CD11c+.

 


View larger version (29K):
[in this window]
[in a new window]
  		FIGURE 5. Heat inactivation or inhibition of viral replication do not modify the failure of {gamma}HV68 infection to induce or up-regulate expression of DC surface molecules. A, Infection of DC cultures with heat-inactivated {gamma}HV68 does not induce up-regulation of cell surface markers (MOI:10). B, Addition of phosphonoacetic acid, an inhibitor of the viral polymerase, to the cell culture medium does not induce up-regulation of DC markers. The histogram populations were gated previously as CD11c+ DCs.

 
{gamma}HV68 infection induces IL-10 production in activated DCs

We have shown that {gamma}HV68 infection of DCs does not induce surface expression of most cell surface markers associated with activation. As only fully mature DCs (IL-12 producers) are potent inducers of immunity (30), we next examined whether viral infection impacts cytokine production associated with DC maturation by analyzing cytokine levels in the supernatants of infected DC cultures (Fig. 6). The results show that {gamma}HV68 infection in the absence of other activation signals does not induce secretion of proinflammatory cytokines, including IL-1{alpha}, IL-1{beta}, IL-6, IL-12p70, and TNF-{alpha}. In addition, {gamma}HV68 infection did not block LPS-induced secretion of proinflammatory cytokines, although there were modest changes in the secretion of IL-1{beta}, IL-6, and IL-12.



View larger version (20K):
[in this window]
[in a new window]
  		FIGURE 6. Analysis of cytokine production in DC culture supernatants 96 h after {gamma}HV68 infection (MOI:2). The data presented are the mean and SD of triplicate wells from one of three representative experiments.

 
DCs control T cell polarization, and some viruses try to affect the normal development of a Th1 immune response by inducing DCs to produce immunosuppressive or Th2-type factors (31). Thus, we also analyzed the secretion of IL-10 in the supernatants of infected DC cultures (Fig. 6). The data show that {gamma}HV68 infection in the absence of other activation signals did not induce IL-10 production. However, {gamma}HV68 infection greatly enhanced the ability of LPS-stimulated DCs to produce IL-10. IL-10 was first recognized for its ability to inhibit activation and effector function of T cells, monocytes, and macrophages (32). Thus, {gamma}HV68-enhanced secretion of an immunosuppressive cytokine by DCs may provide an infectious advantage to the virus.

Viral induction of IL-10 is a strategy used by another {gamma}-herpesvirus, EBV, which encodes an IL-10 homologue (BCRF-1) (33). Endogenous levels of IL-10 have also been shown to increase after {gamma}HV68 infection of mice (34). To corroborate whether the induction of IL-10 observed in DC cultures could have biological significance, we determined whether DCs isolated from infected mice expressed IL-10. We sorted DCs from the lung and spleen of mice at days 5 and 14 after infection and analyzed IL-10 expression by real-time PCR (Fig. 7). The data show a marked increase in IL-10 mRNA expression in DCs isolated from infected mice, especially in lung (5 and 14 dpi) and spleen (14 dpi). Therefore, {gamma}HV68 infection induces IL-10 production by dendritic cells both in culture and during the course of an in vivo infection.



View larger version (14K):
[in this window]
[in a new window]
  		FIGURE 7. IL-10 expression in DCs isolated from lung and spleen at days 5 and 14 after {gamma}HV68 infection was determined by real-time PCR, as indicated in the Materials and Methods. FACS-sorted DC populations were >95% pure.

 
{gamma}HV68 infection of dendritic cells inhibits the proliferation of T cells

It has been reported that {gamma}HV68 interferes with Ag presentation by inducing MHC class I down-regulation (29, 35). However, our analysis of infected DCs in vitro showed no evidence for MHC down-regulation (Fig. 4). To explore the impact of {gamma}HV68 infection on functional Ag presentation, we determined the capacity of infected DCs, with or without LPS stimulation, to process and express virus-specific Ags, as assessed by induction of IL-2 secretion by a panel of {gamma}HV68-specific T cell hybridomas (26, 36). T cell hybridoma stimulation is much less stringent than that of naive T cells because it is independent of costimulation. Therefore, this experimental approach allows us to determine exclusively the capacity of the infected cells to process and express viral Ags. As shown in Fig. 8, the ability of infected DCs to stimulate T cell hybridomas confirmed expression of {gamma}HV68-specific Ags on their cell surface. The data also indicate that LPS-induced stimulation did not alter the stimulatory capacity of the infected DCs. This result was unexpected in light of the different levels of surface expression of MHC molecules detected in infected DCs with and without LPS-induced activation (Fig. 4).



View larger version (18K):
[in this window]
[in a new window]
  		FIGURE 8. {gamma}HV68-infected DCs process and express viral epitope-MHC complexes on the cell surface. The figure shows the relative response of three virus-specific T cell hybridomas (Kb-, Db-, and IAb-restricted) after stimulation with {gamma}HV68-infected DCs. Positive controls (peptide-loaded DCs) and negative controls (naive DCs) were routinely included.

 
Next, we determined the capacity of infected DCs to stimulate normal T cells in an allogeneic mixed lymphocyte response, a standard functional readout for pathogen-infected DCs (37, 38, 39, 40). As shown in Fig. 9A, {gamma}HV68 infection of cultured DCs interfered with the LPS induced-activation of allogeneic T cells. Because the T cell hybridoma experiments indicate that the virus does not interfere with the cell surface expression of functional virus-specific peptide/MHC complexes, the data suggest that {gamma}HV68 interferes with T cell stimulation per se, either because of inadequate costimulation or due to the enhanced production of the immunosuppressive cytokine, IL-10. Next, we cocultured DCs with and without {gamma}HV68 in the presence of allogenic T cells and anti-IL-10 blocking Abs. The data show that blocking Ab reduced the suppressive activity in the infected samples (Fig. 9B). Thus, our results indicate {gamma}HV68-infected DCs can generate IL-10-dependent suppression upon culture with allogenic T cells.



View larger version (16K):
[in this window]
[in a new window]
  		FIGURE 9. {gamma}HV68 infection of DCs inhibits T cell proliferation in a MLR. A, DCs were infected or not with {gamma}HV68 and then added to allogenic T cells. T cell proliferation was assessed by incorporation of [3H]thymidine. B, Neutralizing anti-IL-10 Ab was added at 10 µg/ml to LPS-activated DCs, and T cell proliferation was assessed by CFSE dilution. The data are from one of two experiments with similar results.

 
Lack of IL-10 decreases {gamma}HV68 latency without modulating acute viral infection

To further study the role of IL-10 during {gamma}-herpesvirus infection, we analyzed the consequences of the lack of IL-10 on the viral load in {gamma}HV68-infected mice. IL-10–/– mice were intranasally infected, and the titers of infectious and latent virus were determined in lung and spleen, respectively. The data show no significant differences in levels of infectious virus in IL-10 –/– and control mice, as determined by plaque assay of day 7 lung tissue homogenates (Fig. 10A). Consistent with previous reports, determination of the numbers of latently infected cells in the spleen analyzed by an infective center assay at day 14 show statistically significant lower levels of latently infected cells in mice lacking IL-10 (Fig. 10B). In addition, this reduction in viral latency was maintained during long-term infection (3 mo), as assessed by LDA-PCR (Fig. 10C). Thus, the absence of IL-10 decreases the establishment and maintenance of {gamma}HV68 latency in the spleen without affecting acute viral replication in the lung.



View larger version (13K):
[in this window]
[in a new window]
  		FIGURE 10. Analysis of {gamma}HV68 infection in the absence of host IL-10. C56BL/6 (B6) wild-type mice and IL-10 –/– mice were intranasally infected with {gamma}HV68. A, Infectious virus titers in the lung at day 7 were determined by plaque assay. B, The numbers of latently infected cells in the spleen at day 14 were determined by an infective center assay. The statistical significance of the difference in latent virus was determined by Student’s t test (p = 0.007). C, The numbers of latently infected cells in the spleen at day 90 after infection was determined by LDA-PCR (p = 0.01).

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
Disclosures
 References
 
Our current findings, that DCs are an early target and long-term reservoir for {gamma}HV68 latency and that viral infection of DCs impairs their function, support the possibility that infection of DCs may confer a selective advantage for the {gamma}2-herpesviruses, as has been postulated for other chronic viruses such as HIV (41), human herpes virus-6 (38), HSV-1 (42), murine cytomegalovirus (39), and lymphocytic choriomeningitis virus (43). First, using an in vivo mouse model, we have shown that respiratory DCs at the mucosal site of infection are latently infected at high frequencies very early during acute primary infection and that all the subsets of splenic dendritic cells analyzed contribute to the viral reservoir during the establishment and long-term latency phase of infection. Second, we developed an in vitro model in which {gamma}HV68 productively infects bone marrow-derived DC cultures without immediate induction of cytopathic effect to determine the consequences of {gamma}-herpesvirus interaction with the host cell and to examine the functional impact of viral infection on DC function. The data show that {gamma}HV68 infection did not induce cellular activation or modulation of relevant cell surface costimulatory and MHC molecules. However, the infected DCs could be activated by addition of LPS to the culture. Thus, {gamma}HV68 infection neither induces DC maturation, nor does it prevent the activation of infected DCs by other stimuli. The data also show that although infected DCs stimulated IL-2 production by T cell hybridomas, they were unable to stimulate normal T cells in an allogeneic T cell stimulation assay. This T cell regulation was partially dependent on IL-10. Third, we also show that DCs from infected mice expressed high levels of IL-10 and that absence of IL-10 contributed to decrease the amount of virus during the latent phase of infection.

Primary mouse B cells are inefficiently infected with {gamma}HV68, although the virus induces cellular phenotypic changes (44, 45). The failure of {gamma}HV68 to circularize after virus internalization in primary lymphocytes is thought to underlie the inability of the virus to transform or replicate in these cultures (46). In contrast with B cell infection, we found that {gamma}HV68 infection of DCs failed to induce an activated surface phenotype. DCs also did not secrete type 1 cytokines in response to {gamma}HV68 infection unless they were exogenously stimulated. In addition, {gamma}HV68-activated DCs secreted large amounts of IL-10, which suggests that viral infection and cellular activation have a synergistic effect on IL-10 production. IL-10 exhibits potent immunosuppressive activity during both type 1 and type 2 immune responses (32), and pulmonary DCs producing IL-10 mediate tolerance (47). Production of IL-10 partially contributes to the failure of infected, exogenously activated DCs to stimulate normal T cells in an allogeneic response.

Modulation of early DC function appears to be a common underlying theme for the {gamma}-herpesviruses but appears to be accomplished in different ways for the {gamma}1- and {gamma}2-herpesviruses. EBV, the prototypic {gamma}1-herpesvirus, does not infect DCs (48) but inhibits their development by promoting apoptosis of their precursors (49). KSHV and {gamma}HV68, both {gamma}2-herpesviruses, have similar mechanisms in that they directly infect and establish reservoirs in DCs. KSHV has been detected in monocytes and DCs (11), and there is evidence for functional impairment of DCs isolated from patients with Kaposi’s sarcoma (13). Understanding the mechanism of this impairment has been hampered, until now, by the lack of relevant in vitro models of infection. The initial characterization of an in vitro model of {gamma}HV68 infection reported here will allow a detailed analysis of the consequences of {gamma}2-herpesvirus infection on DC function. Many viruses are capable of infecting DCs and interfering with their function in vitro (50). However, due to the different conditions of infection in culture and to the unclear relationship between cultured and tissue DCs, these results have to be carefully extrapolated to the host. The early and broad spectrum of {gamma}HV68 infection of DCs in vivo and the fact that DCs express increased amounts of IL-10 during in vivo infection supports its relevance as a possible immune evasion strategy.

IL-10 induction appears to be a common immune evasion strategy for the establishment of a variety of chronic viral infections, including the {gamma}-herpesviruses. For example, HIV-1-infected DCs elicit IL-10 production and T cell regulation (41). In addition, IL-10 production is associated both with KSHV and EBV infections. Primary effusion lymphoma cells, a type of lymphoma associated with KSHV infection, release IL-10 (51). EBV expresses a vIL-10 homologue (31) and also induces transformed cells to produce IL-10 (52). The role of IL-10 in EBV-related diseases is remarkable to the extent that IL-10 levels in serum are correlated with EBV load and serve as an early diagnostic assay for non-Hodgkin’s lymphoma (53) and posttransplant lymphoproliferative disorders (54). Our observation that {gamma}HV68 infection of bone marrow-derived DCs promotes the secretion of IL-10, a cytokine that has an inhibitory effect on immune responses (32) and that {gamma}HV68 infection can generate IL-10 dependent suppression of allogenic T cell responses, is consistent with data from several other viral infections (55, 56, 57, 58, 59, 60). In addition, we showed that DCs isolated from infected mice produce large amounts of IL-10 in vivo. Consistent with an important role for IL-10 in {gamma}HV68 infection, previous analysis of {gamma}HV68-infected IL-10 –/– mice showed an increase in virus-induced splenomegaly and leukocytosis and reduced viral latency (34). We also demonstrated decreased {gamma}HV68 latency in the spleens of IL-10 –/– mice, both at the peak of latency (day 14 postinfection) and after the establishment of stable, long-term latency (day 90 postinfection). Importantly, there was no modulation of infectious virus titers during acute viral infection in the lung. These findings suggest that viral induction of host IL-10 production contributes to increase the number of latently infected cells independent of the acute infection.

Our phenotypic analysis showed no evidence for down-modulation of MHC class I molecules, and analysis of functional Ag presentation, detected by the ability to stimulate virus-specific T cell hybridomas, showed no evidence for virus-induced impairment. This observation contrasts with other studies indicating that {gamma}HV68 induces MHC class I surface down-regulation, as a consequence of ubiquitination of class I molecules and TAP degradation by the virally encoded K3 gene product (29, 61). Analysis following infection with K3-deficient {gamma}HV68 showed no effect on clearance of lytic virus but demonstrated an impact on the establishment of latency (35). As our gene expression analysis shows that infected DCs express K3, our failure to observe class I down-modulation after infection of DCs is unexpected. Down-regulation of MHC class I has been reported for infected fibroblasts and transfected cell lines (29, 61), raising the intriguing possibility that the Ag presentation machinery of DCs is efficient to overcome the effects of K3. Cell type-specific differences in MHC class I down-regulation have also been described for HSV-1, where ICP47-TAP interactions vary between cell types (62, 63, 64).

Early {gamma}HV68 infection of DCs is consistent with two possible immune evasion strategies. First, early lytic infection of DCs would result in their death and the release of progeny virus. However, {gamma}HV68-infected cultured DCs do not undergo immediate cytopathic effect. Second, early latent infection of DCs might result in functional modulation. Our data support this latter possibility that {gamma}HV68 establishes a latent infection in DCs and impairs DC function. The detection of episomal and linear {gamma}HV68 DNA in lung DCs and the establishment of long-term latency in spleen DCs is consistent with latent infection of DCs. In addition, the demonstration that {gamma}HV68 infection induces increased IL-10 secretion by LPS-stimulated DCs suggests a possible mechanism of functional modulation.

Despite the impact of infection on DC function demonstrated in this study, a vigorous immune response is mounted against {gamma}HV68. However, the early response to {gamma}HV68, as with EBV, is largely directed against lytic epitopes (65, 66). The lytic infection may serve as a decoy to "distract" the immune response and allow latent virus to sneak through. In support of this, T cells responding to the single latent epitope characterized are not detectable in the lung, mesenteric lymph node, or spleen until 19 days postinfection (67). We propose that early infection of DCs results in functional modulation, biasing the initiation of the immune response toward lytic instead of latent epitopes. The vigorous T cell response to epitopes of lytic cycle proteins, which are produced in larger amounts than latent cycle proteins in dying cells where the virus replicates, is likely driven by cross-presentation and cross-priming by non-{gamma}HV68-infected DCs. Thus, we propose that despite strong antiviral immunity, the relative reduction in response to latent vs lytic Ags may help latent virus to establish a foothold in the host.


   Acknowledgments
 
We thank Simon Monard, Brandon Sells, and the Trudeau Institute Flow Cytometry Facility for assistance with the FACS sorting; Scottie Adams, Jessica Hoffman, and the Trudeau Institute Molecular Biology Facility for the real-time PCR analysis of IL-10; and John Moore for technical assistance.


   Disclosures
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
References
 
The authors have no financial conflict of interest.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by National Institutes of Health Grants AI42927 (to M.A.B.), AI51602 (to M.A.B.), and AI59603 (to E.F.), the Trudeau Institute, and the Columbus Children’s Research Institute. Back

2 Address correspondence and reprint requests to Dr. Marcia A. Blackman, Trudeau Institute, 154 Algonquin Avenue, Saranac Lake, NY 12983. E-mail address: mblackman{at}trudeauinstitute.org Back

3 Abbreviations used in this paper: DC, dendritic cell; KSHV, Kaposi’s sarcoma-associated herpesvirus; MOI, multiplicity of infection; LDA, limiting dilution analysis; dpi, days postinfection. Back

Received for publication September 1, 2004. Accepted for publication June 14, 2005.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 

  1. Mellman, I., R. M. Steinman. 2001. Dendritic cells: specialized and regulated antigen processing machines. Cell 106:255.-258. [Medline]
  2. Lanzavecchia, A., F. Sallusto. 2001. Regulation of T cell immunity by dendritic cells. Cell 106:263.-266. [Medline]
  3. Banchereau, J., R. M. Steinman. 1998. Dendritic cells and the control of immunity. Nature 392:245.-252. [Medline]
  4. Bell, D., J. W. Young, J. Banchereau. 1999. Dendritic cells. Adv. Immunol. 72:255.-324. [Medline]
  5. Banchereau, J., F. Briere, C. Caux, J. Davoust, S. Lebecque, Y. J. Liu, B. Pulendran, K. Palucka. 2000. Immunobiology of dendritic cells. Annu. Rev. Immunol. 18:767.-811. [Medline]
  6. Liu, Y. J.. 2001. Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. Cell 106:259.-262. [Medline]
  7. Rescigno, M., P. Borrow. 2001. The host-pathogen interaction: new themes from dendritic cell biology. Cell 106:267.-270. [Medline]
  8. Palucka, K., J. Banchereau. 2002. How dendritic cells and microbes interact to elicit or subvert protective immune responses. Curr. Opin. Immunol. 14:420.-431. [Medline]
  9. Moore, P. S., Y. Chang. 2003. Kaposi’s sarcoma-associated herpesvirus immunoevasion and tumorigenesis: two sides of the same coin?. Annu. Rev. Microbiol. 57:609.-639. [Medline]
  10. Offermann, M. K.. 1999. Consideration of host-viral interactions in the pathogenesis of Kaposi’s sarcoma. J. Acquir. Immune Defic. Syndr. 21:(Suppl. 1):S58.-S65.
  11. Rettig, M. B., H. J. Ma, R. A. Vescio, M. Pold, G. Schiller, D. Belson, A. Savage, C. Nishikubo, C. Wu, J. Fraser, J. W. Said, J. R. Berenson. 1997. Kaposi’s sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients. Science 276:1851.-1854. [Abstract/Free Full Text]
  12. Schulz, T. F.. 1998. Kaposi’s sarcoma-associated herpesvirus (human herpesvirus-8). J. Gen. Virol. 79:(Pt. 7):1573.-1591. [Medline]
  13. Stebbing, J., B. Gazzard, S. Portsmouth, F. Gotch, L. Kim, M. Bower, S. Mandalia, R. Binder, P. Srivastava, S. Patterson. 2003. Disease-associated dendritic cells respond to disease-specific antigens through the common heat shock protein receptor. Blood 102:1806.-1814. [Abstract/Free Full Text]
  14. Virgin, H. W., P. Latreille, P. Wamsley, K. Hallsworth, K. E. Weck, A. J. Dal Canto, S. H. Speck. 1997. Complete sequence and genomic analysis of murine gammaherpesvirus 68. J. Virol. 71:5894.-5904. [Abstract]
  15. Virgin, H. W., S. H. Speck. 1999. Unraveling immunity to {gamma}-herpesviruses: a new model for understanding the role of immunity in chronic virus infection. Curr. Opin. Immunol. 11:371.-379. [Medline]
  16. Doherty, P. C., J. P. Christensen, G. T. Belz, P. G. Stevenson, M. Y. Sangster. 2001. Dissecting the host response to a {gamma}-herpesvirus. Philos. Trans. R. Soc. Lond. B Biol. Sci. 356:581.-593. [Abstract/Free Full Text]
  17. Flaño, E., S. M. Husain, J. T. Sample, D. L. Woodland, M. A. Blackman. 2000. Latent murine {gamma}-herpesvirus infection is established in activated B cells, dendritic cells, and macrophages. J. Immunol. 165:1074.-1081. [Abstract/Free Full Text]
  18. Flaño, E., I. J. Kim, J. Moore, D. L. Woodland, M. A. Blackman. 2003. Differential {gamma}-herpesvirus distribution in distinct anatomical locations and cell subsets during persistent infection in mice. J. Immunol. 170:3828.-3834. [Abstract/Free Full Text]
  19. Stewart, J. P., E. J. Usherwood, A. Ross, H. Dyson, T. Nash. 1998. Lung epithelial cells are a major site of murine gammaherpesvirus persistence. J. Exp. Med. 187:1941.-1951. [Abstract/Free Full Text]
  20. Weck, K. E., S. S. Kim, H. W. Virgin, S. H. Speck. 1999. Macrophages are the major reservoir of latent murine gammaherpesvirus 68 in peritoneal cells. J. Virol. 73:3273.-3283. [Abstract/Free Full Text]
  21. Flaño, E., I. J. Kim, D. L. Woodland, M. A. Blackman. 2002. {gamma}-Herpesvirus latency is preferentially maintained in splenic germinal center and memory B cells. J. Exp. Med. 196:1363.-1372. [Abstract/Free Full Text]
  22. Virgin, H. W., R. M. Presti, X. Y. Li, C. Liu, S. H. Speck. 1999. Three distinct regions of the murine gammaherpesvirus 68 genome are transcriptionally active in latently infected mice. J. Virol. 73:2321.-2332. [Abstract/Free Full Text]
  23. Gardella, T., P. Medveczky, T. Sairenji, C. Mulder. 1984. Detection of circular and linear herpesvirus DNA molecules in mammalian cells by gel electrophoresis. J. Virol. 50:248.-254. [Abstract/Free Full Text]
  24. Decker, L. L., G. J. Babcock, D. A. Thorley-Lawson. 2001. Detection and discrimination of latent and replicative herpesvirus infection at the single cell level in vivo. Methods Mol. Biol. 174:111.-116. [Medline]
  25. Flaño, E., Q. Jia, J. Moore, D. L. Woodland, R. Sun, M. A. Blackman. 2005. Early establishment of {gamma}-herpesvirus latency: implications for immune control. J. Immunol. 174:4972.-4978. [Abstract/Free Full Text]
  26. Liu, L., E. Flaño, E. J. Usherwood, S. Surman, M. A. Blackman, D. L. Woodland. 1999. Lytic cycle T cell epitopes are expressed in two distinct phases during MHV-68 infection. J. Immunol. 163:868.-874. [Abstract/Free Full Text]
  27. Overbergh, L., D. Valckx, M. Waer, C. Mathieu. 1999. Quantification of murine cytokine mRNAs using real time quantitative reverse transcriptase PCR. Cytokine 11:305.-312. [Medline]
  28. Bechtel, J. T., Y. Liang, J. Hvidding, D. Ganem. 2003. Host range of Kaposi’s sarcoma-associated herpesvirus in cultured cells. J. Virol. 77:6474.-6481. [Abstract/Free Full Text]
  29. Stevenson, P. G., S. Efstathiou, P. C. Doherty, P. J. Lehner. 2000. Inhibition of MHC class I-restricted antigen presentation by {gamma}2-herpesviruses. Proc. Natl. Acad. Sci. USA 97:8455.-8460. [Abstract/Free Full Text]
  30. Lutz, M. B., G. Schuler. 2002. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity?. Trends Immunol. 23:445.-449. [Medline]
  31. Alcami, A., U. H. Koszinowski. 2000. Viral mechanisms of immune evasion. Immunol. Today 21:447.-455. [Medline]
  32. Moore, K. W., R. de Waal Malefyt, R. L. Coffman, A. O’Garra. 2001. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19:683.-765. [Medline]
  33. Rickinson, A. B., E. Kieff. 1996. Epstein-Barr virus. D. M. Knipe, and B. N. Fields, and P. M. Howley, eds. Fields Virology 2397.-2446. Lippincott-Raven Publishers, Philadelphia.
  34. Peacock, J. W., K. L. Bost. 2001. Murine gammaherpesvirus-68-induced interleukin-10 increases viral burden, but limits virus-induced splenomegaly and leukocytosis. Immunology 104:109.-117. [Medline]
  35. Stevenson, P. G., J. S. May, X. G. Smith, S. Marques, H. Adler, U. H. Koszinowski, J. P. Simas, S. Efstathiou. 2002. K3-mediated evasion of CD8+ T cells aids amplification of a latent gammaherpesvirus. Nat. Immunol. 3:733.-740. [Medline]
  36. Flaño, E., D. L. Woodland, M. A. Blackman, P. C. Doherty. 2001. Analysis of virus-specific CD4+ T cells during long-term gammaherpesvirus infection. J. Virol. 75:7744.-7748. [Abstract/Free Full Text]
  37. Mahanty, S., K. Hutchinson, S. Agarwal, M. McRae, P. E. Rollin, B. Pulendran. 2003. Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses. J. Immunol. 170:2797.-2801. [Abstract/Free Full Text]
  38. Kakimoto, M., A. Hasegawa, S. Fujita, M. Yasukawa. 2002. Phenotypic and functional alterations of dendritic cells induced by human herpesvirus 6 infection. J. Virol. 76:10338.-10345. [Abstract/Free Full Text]
  39. Andrews, D. M., C. E. Andoniou, F. Granucci, P. Ricciardi-Castagnoli, M. A. Degli-Esposti. 2001. Infection of dendritic cells by murine cytomegalovirus induces functional paralysis. Nat. Immunol. 2:1077.-1084. [Medline]
  40. Engelmayer, J., M. Larsson, M. Subklewe, A. Chahroudi, W. I. Cox, R. M. Steinman, N. Bhardwaj. 1999. Vaccinia virus inhibits the maturation of human dendritic cells: a novel mechanism of immune evasion. J. Immunol. 163:6762.-6768. [Abstract/Free Full Text]
  41. Granelli-Piperno, A., A. Golebiowska, C. Trumpfheller, F. P. Siegal, R. M. Steinman. 2004. HIV-1-infected monocyte-derived dendritic cells do not undergo maturation but can elicit IL-10 production and T cell regulation. Proc. Natl. Acad. Sci. USA 101:7669.-7674. [Abstract/Free Full Text]
  42. Salio, M., M. Cella, M. Suter, A. Lanzavecchia. 1999. Inhibition of dendritic cell maturation by herpes simplex virus. Eur. J. Immunol. 29:3245.-3253. [Medline]
  43. Sevilla, N., S. Kunz, A. Holz, H. Lewicki, D. Homann, H. Yamada, K. P. Campbell, J. C. de La Torre, M. B. Oldstone. 2000. Immunosuppression and resultant viral persistence by specific viral targeting of dendritic cells. J. Exp. Med. 192:1249.-1260. [Abstract/Free Full Text]
  44. Dutia, B. M., J. P. Stewart, R. A. Clayton, H. Dyson, A. A. Nash. 1999. Kinetic and phenotypic changes in murine lymphocytes infected with murine gammaherpesvirus-68 in vitro. J. Gen. Virol. 80:(Pt. 10):2729.-2736. [Abstract/Free Full Text]
  45. Stevenson, P. G., P. C. Doherty. 1999. Non-antigen-specific B-cell activation following murine gammaherpesvirus infection is CD4 independent in vitro but CD4 dependent in vivo. J. Virol. 73:1075.-1079. [Abstract/Free Full Text]
  46. Nash, A. A., B. M. Dutia, J. P. Stewart, A. J. Davison. 2001. Natural history of murine gammaherpesvirus infection. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 356:569.-579. [Abstract/Free Full Text]
  47. Akbari, O., R. H. DeKruyff, D. T. Umetsu. 2001. Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat. Immunol. 2:725.-731. [Medline]
  48. Bickham, K., K. Goodman, C. Paludan, S. Nikiforow, M. L. Tsang, R. M. Steinman, C. Munz. 2003. Dendritic cells initiate immune control of Epstein-Barr virus transformation of B lymphocytes in vitro. J. Exp. Med. 198:1653.-1663. [Abstract/Free Full Text]
  49. Li, L., D. Liu, L. Hutt-Fletcher, A. Morgan, M. G. Masucci, V. Levitsky. 2002. Epstein-Barr virus inhibits the development of dendritic cells by promoting apoptosis of their monocyte precursors in the presence of granulocyte macrophage-colony-stimulating factor and interleukin-4. Blood 99:3725.-3734. [Abstract/Free Full Text]
  50. Yewdell, J. W., A. B. Hill. 2002. Viral interference with antigen presentation. Nat. Immunol. 3:1019.-1025. [Medline]
  51. Jones, K. D., Y. Aoki, Y. Chang, P. S. Moore, R. Yarchoan, G. Tosato. 1999. Involvement of interleukin-10 (IL-10) and viral IL-6 in the spontaneous growth of Kaposi’s sarcoma herpesvirus-associated infected primary effusion lymphoma cells. Blood 94:2871.-2879. [Abstract/Free Full Text]
  52. Burdin, N., C. Peronne, J. Banchereau, F. Rousset. 1993. Epstein-Barr virus transformation induces B lymphocytes to produce human interleukin 10. J. Exp. Med. 177:295.-304. [Abstract/Free Full Text]
  53. Blay, J. Y., N. Burdin, F. Rousset, G. Lenoir, P. Biron, T. Philip, J. Banchereau, M. C. Favrot. 1993. Serum interleukin-10 in non-Hodgkin’s lymphoma: a prognostic factor. Blood 82:2169.-2174. [Abstract/Free Full Text]
  54. Muti, G., C. Klersy, F. Baldanti, S. Granata, P. Oreste, L. Pezzetti, M. Gatti, L. Gargantini, M. Caramella, V. Mancini, G. Gerna, E. Morra. 2003. Epstein-Barr virus (EBV) load and interleukin-10 in EBV-positive and EBV-negative post-transplant lymphoproliferative disorders. Br. J. Haematol. 122:927.-933. [Medline]
  55. Arena, A., M. C. Liberto, D. Iannello, A. B. Capozza, A. Foca. 1999. Altered cytokine production after human herpes virus type 6 infection. New Microbiol. 22:293.-300. [Medline]
  56. van Den Broek, M., M. F. Bachmann, G. Kohler, M. Barner, R. Escher, R. Zinkernagel, M. Kopf. 2000. IL-4 and IL-10 antagonize IL-12-mediated protection against acute vaccinia virus infection with a limited role of IFN-{gamma} and nitric oxide synthetase 2. J. Immunol. 164:371.-378. [Abstract/Free Full Text]
  57. Stockl, J., H. Vetr, O. Majdic, G. Zlabinger, E. Kuechler, W. Knapp. 1999. Human major group rhinoviruses down-modulate the accessory function of monocytes by inducing IL-10. J. Clin. Invest. 104:957.-965. [Medline]
  58. Redpath, S., A. Angulo, N. R. Gascoigne, P. Ghazal. 1999. Murine cytomegalovirus infection down-regulates MHC class II expression on macrophages by induction of IL-10. J. Immunol. 162:6701.-6707. [Abstract/Free Full Text]
  59. Lin, M. T., D. R. Hinton, B. Parra, S. A. Stohlman, R. C. van der Veen. 1998. The role of IL-10 in mouse hepatitis virus-induced demyelinating encephalomyelitis. Virology 245:270.-280. [Medline]
  60. Rowell, J. F., D. E. Griffin. 1999. The inflammatory response to nonfatal Sindbis virus infection of the nervous system is more severe in SJL than in BALB/c mice and is associated with low levels of IL-4 mRNA and high levels of IL-10-producing CD4+ T cells. J. Immunol. 162:1624.-1632. [Abstract/Free Full Text]
  61. Boname, J. M., P. G. Stevenson. 2001. MHC class I ubiquitination by a viral PHD/LAP finger protein. Immunity 15:627.-636. [Medline]
  62. Jugovic, P., A. M. Hill, R. Tomazin, H. Ploegh, D. C. Johnson. 1998. Inhibition of major histocompatibility complex class I antigen presentation in pig and primate cells by herpes simplex virus type 1 and 2 ICP47. J. Virol. 72:5076.-5084. [Abstract/Free Full Text]
  63. Raftery, M. J., C. K. Behrens, A. Muller, P. H. Krammer, H. Walczak, G. Schonrich. 1999. Herpes simplex virus type 1 infection of activated cytotoxic T cells: induction of fratricide as a mechanism of viral immune evasion. J. Exp. Med. 190:1103.-1114. [Abstract/Free Full Text]
  64. Mikloska, Z., L. Bosnjak, A. L. Cunningham. 2001. Immature monocyte-derived dendritic cells are productively infected with herpes simplex virus type 1. J. Virol. 75:5958.-5964. [Abstract/Free Full Text]
  65. Hislop, A. D., N. E. Annels, N. H. Gudgeon, A. M. Leese, A. B. Rickinson. 2002. Epitope-specific evolution of human CD8+ T cell responses from primary to persistent phases of Epstein-Barr virus infection. J. Exp. Med. 195:893.-905. [Abstract/Free Full Text]
  66. Stevenson, P. G., G. T. Belz, J. D. Altman, P. C. Doherty. 1999. Changing patterns of dominance in the CD8+ T cell response during acute and persistent murine {gamma}-herpesvirus infection. Eur. J. Immunol. 29:1059.-1067. [Medline]
  67. Obar, J. J., S. G. Crist, D. C. Gondek, E. J. Usherwood. 2004. Different functional capacities of latent and lytic antigen-specific CD8 T cells in murine gammaherpesvirus infection. J. Immunol. 172:1213.-1219. [Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 J. Immunol.Home page
B. Kayhan, E. J. Yager, K. Lanzer, T. Cookenham, Q. Jia, T.-T. Wu, D. L. Woodland, R. Sun, and M. A. Blackman
A Replication-Deficient Murine {gamma}-Herpesvirus Blocked in Late Viral Gene Expression Can Establish Latency and Elicit Protective Cellular Immunity
J. Immunol., December 15, 2007; 179(12): 8392 - 8402.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. A. Smith, S. Efstathiou, and A. Cooke
Murine Gammaherpesvirus-68 Infection Alters Self-Antigen Presentation and Type 1 Diabetes Onset in NOD Mice
J. Immunol., December 1, 2007; 179(11): 7325 - 7333.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
F. Kupresanin, J. Chow, A. Mount, C. M. Smith, P. G. Stevenson, and G. T. Belz
Dendritic Cells Present Lytic Antigens and Maintain Function throughout Persistent {gamma}-Herpesvirus Infection
J. Immunol., December 1, 2007; 179(11): 7506 - 7513.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
J. L. Weslow-Schmidt, N. A. Jewell, S. E. Mertz, J. P. Simas, J. E. Durbin, and E. Flano
Type I Interferon Inhibition and Dendritic Cell Activation during Gammaherpesvirus Respiratory Infection
J. Virol., September 15, 2007; 81(18): 9778 - 9789.
[Abstract] [Full Text] [PDF]

Home page
 J. Gen. Virol.Home page
R. Hochreiter, C. Ptaschinski, S. L. Kunkel, and R. Rochford
Murine gammaherpesvirus-68 productively infects immature dendritic cells and blocks maturation
J. Gen. Virol., July 1, 2007; 88(7): 1896 - 1905.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Flaño, E.
Right arrow Articles by Blackman, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Flaño, E.
Right arrow Articles by Blackman, M. A.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS